TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME
Brief Summary: The goal of the proposed project is to see if an innovative family-based intervention can reduce childhood obesity by actively engaging the whole family in promoting healthy behaviors in the home. In addition, the project will also examine how the NU-HOME family intervention influences children's dietary intake, availability of healthy and unhealthy foods in the home and served at meals and snacks, physical activity as a family, and child screen time (TV, game systems). The study will build upon a similar project conducted in an urban area and translate the lessons learned and adapt the program for a rural community.


Options:
A: Arm Label: NU-HOME Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: NU-HOME Intervention | Arm Label: Delayed Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NU-HOME Intervention; Assigned to Arm(s): NU-HOME Intervention
B: Arm Label: Enhanced usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ED-only; Type: EXPERIMENTAL; Interventions: Behavioral: CAPE | Arm Label: ED-plus-home; Type: EXPERIMENTAL; Interventions: Behavioral: CAPE, Behavioral: CHW home visits | Intervention Type: BEHAVIORAL; Name: CAPE; Assigned to Arm(s): ED-only, ED-plus-home | Intervention Type: BEHAVIORAL; Name: CHW home visits; Assigned to Arm(s): ED-plus-home
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telehealth Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telehealth Intervention | Intervention Type: BEHAVIORAL; Name: Telehealth Intervention; Assigned to Arm(s): Telehealth Intervention
D: Arm Label: Multifaceted Strategy; Type: EXPERIMENTAL; Interventions: Behavioral: Multifaceted Strategy | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multifaceted Strategy; Assigned to Arm(s): Multifaceted Strategy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.
Brief Summary: The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis. Participants were placed into 1 of 3 groups to receive M2951, placebo or tecfidera for 24 weeks. After 24 weeks, the participants on placebo were given M2951.


Options:
A: Arm Label: methylprednisolone PO; Type: EXPERIMENTAL; Interventions: Drug: methylprednisolone PO | Arm Label: methylprednisolone IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone IV | Intervention Type: DRUG; Name: methylprednisolone PO; Assigned to Arm(s): methylprednisolone PO | Intervention Type: DRUG; Name: methylprednisolone IV; Assigned to Arm(s): methylprednisolone IV
B: Arm Label: Placebo then Evobrutinib 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Evobrutinib | Arm Label: Evobrutinib 25 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Evobrutinib 75 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Evobrutinib 75 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Evobrutinib | Arm Label: Tecfidera; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tecfidera | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 75 mg BID | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 25 mg QD | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Evobrutinib 75 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Placebo then Evobrutinib 25 mg QD | Intervention Type: DRUG; Name: Tecfidera; Assigned to Arm(s): Tecfidera | Intervention Type: DRUG; Name: Evobrutinib; Assigned to Arm(s): Placebo then Evobrutinib 25 mg QD
C: Arm Label: Fingolimod (Gilenya®); Type: EXPERIMENTAL; Interventions: Drug: Verum arm receiving Gilenya® | Arm Label: Interferon beta-1b (Extavia®); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active Comparator receiving Extavia® | Intervention Type: DRUG; Name: Verum arm receiving Gilenya®; Assigned to Arm(s): Fingolimod (Gilenya®) | Intervention Type: DRUG; Name: Active Comparator receiving Extavia®; Assigned to Arm(s): Interferon beta-1b (Extavia®)
D: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Drug: alemtuzumab GZ402673 | Intervention Type: DRUG; Name: alemtuzumab GZ402673; Assigned to Arm(s): Alemtuzumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Box: Using Smart Technology to Improve One-year Outcome of Myocardial Infarction Patients
Brief Summary: Study to investigate whether a smart technology intervention can improve clinical and cost-effectiveness of one-year follow-up in patients who suffered from acute myocardial infarction.


Options:
A: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: vCRP; Type: EXPERIMENTAL; Interventions: Behavioral: vCRP | Intervention Type: BEHAVIORAL; Name: vCRP; Assigned to Arm(s): vCRP
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise training | Arm Label: intensive exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive exercise training | Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): Exercise training | Intervention Type: BEHAVIORAL; Name: Intensive exercise training; Assigned to Arm(s): intensive exercise training
C: Arm Label: Weight Loss; Type: EXPERIMENTAL; Interventions: Other: Weight Loss | Arm Label: Interval Training; Type: EXPERIMENTAL; Interventions: Other: Interval Training | Intervention Type: OTHER; Name: Interval Training; Assigned to Arm(s): Interval Training | Intervention Type: OTHER; Name: Weight Loss; Assigned to Arm(s): Weight Loss
D: Arm Label: The Box; Type: EXPERIMENTAL; Interventions: Other: The Box | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: The Box; Assigned to Arm(s): The Box

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Efficacy of Flapless Corticotomy Accomplished by Piezosurgery in Accelerating Orthodontic Treatment of Crowding in Adults: a Randomized Controlled Trial
Brief Summary: Applying flapless piezocision corticotomies on the alveolar bone and separating anterior mandibular teeth using a piezosurgery device (i.e. ultrasonic waves that perform very accurate incisions without any sutures following this procedure) may improve the speed of tooth alignment during orthodontic treatment. This study consists of two groups, patients will be randomly assigned to one of these two groups. The efficacy of this procedure on 18 patients (experimental group) will be evaluated,whereas the second group (control group) will receive a traditional orthodontic therapy. The time required to achieve complete alignment of crowded mandibular anterior teeth (from canine to canine) will be compared between the two groups.


Options:
A: Arm Label: AcceleDent vibrational device; Type: EXPERIMENTAL; Interventions: Device: AcceleDent vibrational device | Arm Label: Sham AcceleDent device; Type: SHAM_COMPARATOR; Interventions: Device: Sham AcceleDent device | Arm Label: Fixed appliance only; Type: ACTIVE_COMPARATOR; Interventions: Other: Fixed appliance only | Intervention Type: DEVICE; Name: AcceleDent vibrational device; Assigned to Arm(s): AcceleDent vibrational device | Intervention Type: DEVICE; Name: Sham AcceleDent device; Assigned to Arm(s): Sham AcceleDent device | Intervention Type: OTHER; Name: Fixed appliance only; Assigned to Arm(s): Fixed appliance only
B: Arm Label: RME on upper first permanent molars; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rapid maxillary expansion | Arm Label: RME on upper second deciduous molars; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Rapid maxillary expansion | Intervention Type: PROCEDURE; Name: Rapid maxillary expansion; Assigned to Arm(s): RME on upper first permanent molars, RME on upper second deciduous molars
C: Arm Label: Piezosurgery; Type: EXPERIMENTAL; Interventions: Procedure: Piezosurgery | Arm Label: Ordinary Alignment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Piezosurgery; Assigned to Arm(s): Piezosurgery
D: Arm Label: Heat-Activated Nickel-Titanium Archwires; Type: EXPERIMENTAL; Interventions: Procedure: Orthodontic treatment | Arm Label: Superelastic Nickel-Titanium Archwires; Type: EXPERIMENTAL; Interventions: Procedure: Orthodontic treatment | Intervention Type: PROCEDURE; Name: Orthodontic treatment; Assigned to Arm(s): Heat-Activated Nickel-Titanium Archwires, Superelastic Nickel-Titanium Archwires

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Anxiety in Late Adolescents With Autism
Brief Summary: Autism spectrum disorders (ASD) affect approximately 1.1% of late adolescents and young adults, making it one of the most common neurodevelopmental disorders. Comorbid anxiety disorders affect many higher-functioning adolescents and young adults with ASD, causing substantial distress and impairment over and above that caused by an ASD diagnosis alone. While cognitive-behavioral therapy (CBT) is a first-line treatment for anxiety disorders among typically developing late adolescents, and work by the investigative team supports its utility in children with ASD and comorbid anxiety, very few evidence-based treatment approaches exist for late adolescents with ASD and comorbid anxiety. Accordingly, the investigators are proposing to develop a CBT protocol for clinical anxiety that is personalized to the unique clinical characteristics of late adolescents (ages 16-21 years) with ASD namely, the Treatment of Anxiety in Late Adolescents with Autism (TALAA).


Options:
A: Arm Label: Fb-Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Functional Behavior-Based Cognitive Behavioral Therapy | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Functional Behavior-Based Cognitive Behavioral Therapy; Assigned to Arm(s): Fb-Cognitive Behavioral Therapy
B: Arm Label: Cognitive-Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavior Therapy | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavior Therapy; Assigned to Arm(s): Cognitive-Behavior Therapy | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
C: Arm Label: Cognitive Behavioral Therapy Condition; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Therapy | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy Condition | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual
D: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High-Flow Nasal Cannula Oxygen Therapy (HFNC) Alone or Associated With Noninvasive Ventilation (NIV) for Immunocompromised Patients Admitted to Intensive Care Unit for Acute Respiratory Failure : FLORALI-Immunodéprimés
Brief Summary: Acute respiratory failure is the leading cause of ICU admission of immunocompromized patients. In this subgroup of patients, the need for intubation and invasive mechanical ventilation occurs in about 50% of cases and is associated with very a high mortality rate, reaching 70% of cases. Therefore, noninvasive oxygenation strategies have been developed to avoid intubation.

More than 15 years ago, 2 trials have suggested that NIV could decrease intubation and mortality rates of immunocompromized patients as compared to standard oxygen through a mask. However these results have not been confirmed in a recent large trial.

HFNC is a recent and well-tolerated oxygenation technique. In a recent trial, HFNC alone could decrease mortality and intubation rates in patients with ARF as compared to NIV. Similar findings have been reported in a post-hoc analysis on immunocompromized patients excluding those with profound neutropenia. Likewise in a retrospective monocentric cohort of immunocompromized patients, we reported better outcomes with HFNC than with NIV.


Options:
A: Arm Label: HFNT; Type: EXPERIMENTAL; Interventions: Other: HFNT | Arm Label: NIV; Type: ACTIVE_COMPARATOR; Interventions: Other: NIV | Intervention Type: OTHER; Name: HFNT; Assigned to Arm(s): HFNT | Intervention Type: OTHER; Name: NIV; Assigned to Arm(s): NIV
B: Arm Label: Standard oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Arm Label: nasal high flow oxygen therapy; Type: OTHER; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Intervention Type: DEVICE; Name: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand); Assigned to Arm(s): Standard oxygen therapy, nasal high flow oxygen therapy
C: Arm Label: NIV/HFNC group; Type: ACTIVE_COMPARATOR; Interventions: Device: NIV/HFNC | Arm Label: HFNC group; Type: EXPERIMENTAL; Interventions: Device: HFNC | Intervention Type: DEVICE; Name: NIV/HFNC; Assigned to Arm(s): NIV/HFNC group | Intervention Type: DEVICE; Name: HFNC; Assigned to Arm(s): HFNC group
D: Arm Label: Optiflow then CPAP; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Arm Label: CPAP then Optiflow; Type: EXPERIMENTAL; Interventions: Procedure: O2stand, Procedure: CPAP, Procedure: Optiflow | Intervention Type: PROCEDURE; Name: O2stand; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP | Intervention Type: PROCEDURE; Name: Optiflow; Assigned to Arm(s): CPAP then Optiflow, Optiflow then CPAP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy Transferred From the Hospital to Skilled Nursing Facilities
Brief Summary: This randomized, controlled trial will evaluate the effects of an intervention to reduce exposure to medications among hospitalized older adults discharged to skilled nursing facilities (SNFs). The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences. The investigators will evaluate the effects of the intervention on the total number of medications prescribed to patients at hospital and SNF discharge and at home 90-days after SNF discharge along with the prevalence of eight geriatric syndromes, medication adherence, and health status.


Options:
A: Arm Label: Free and convenient medicine access; Type: EXPERIMENTAL; Interventions: Other: Free and convenient medicine access | Arm Label: Usual medicine access; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Free and convenient medicine access; Assigned to Arm(s): Free and convenient medicine access
B: Arm Label: Shed-Meds: A Patient-Centered Deprescribing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Shed-Meds: A Patient-Centered Deprescribing Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shed-Meds: A Patient-Centered Deprescribing Intervention; Assigned to Arm(s): Shed-Meds: A Patient-Centered Deprescribing Intervention
C: Intervention Type: BEHAVIORAL; Name: Early hospital discharge facilitated by close nurse practitioner follow-up; Assigned to Arm(s): N/A
D: Arm Label: group I (early intervention); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: structured educational program | Arm Label: delayed education; Type: OTHER; Interventions: Behavioral: participation in the educational program after 6 months | Intervention Type: BEHAVIORAL; Name: structured educational program; Assigned to Arm(s): group I (early intervention) | Intervention Type: BEHAVIORAL; Name: participation in the educational program after 6 months; Assigned to Arm(s): delayed education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy Transferred From the Hospital to Skilled Nursing Facilities
Brief Summary: This randomized, controlled trial will evaluate the effects of an intervention to reduce exposure to medications among hospitalized older adults discharged to skilled nursing facilities (SNFs). The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences. The investigators will evaluate the effects of the intervention on the total number of medications prescribed to patients at hospital and SNF discharge and at home 90-days after SNF discharge along with the prevalence of eight geriatric syndromes, medication adherence, and health status.


Options:
A: Arm Label: standard course; Type: OTHER; Interventions: Other: pharmacist-led standardized medication review | Arm Label: pharmacist-led standardized medication review; Type: OTHER; Interventions: Other: pharmacist-led standardized medication review | Intervention Type: OTHER; Name: pharmacist-led standardized medication review; Assigned to Arm(s): pharmacist-led standardized medication review, standard course
B: Arm Label: Optimization of drug prescribing; Type: EXPERIMENTAL; Interventions: Other: Optimization of drug prescribing | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Optimization of drug prescribing; Assigned to Arm(s): Optimization of drug prescribing
C: Arm Label: Shed-Meds: A Patient-Centered Deprescribing Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Shed-Meds: A Patient-Centered Deprescribing Intervention | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shed-Meds: A Patient-Centered Deprescribing Intervention; Assigned to Arm(s): Shed-Meds: A Patient-Centered Deprescribing Intervention
D: Arm Label: Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient Navigator, Other: Usual care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient Navigator; Assigned to Arm(s): Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Navigator

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing the Effectiveness of Clinicians and Paraprofessionals to Reduce Disparities in Perinatal Depression
Brief Summary: There is considerable evidence that most perinatal women at risk for postpartum depression do not engage in mental health services, even when referred by home visiting (HV) programs, primary care physicians, obstetricians, or gynecologists. Thus, interventions that can be delivered via alternative settings-e.g., HV programs-are essential to prevent the onset of major depression and worsening of depressive symptoms among perinatal women. This Patient Centered Outcomes Research Institute (PCORI) funded project aims to evaluate whether the Mothers and Babies (MB) group intervention, when led by paraprofessional home visitors, is more efficacious than usual care (i.e., home visiting without the MB enhancement). It will also examine if MB, when led by paraprofessional home visitors, is not inferior to MB delivered by mental health professionals. The results of this study will inform decision-making by HV programs regarding provision of MB to perinatal women at risk for developing major depression.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PRIDE 'Step 1' problem-solving intervention | Intervention Type: BEHAVIORAL; Name: PRIDE 'Step 1' problem-solving intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): Control
B: Arm Label: Trickle Up; Type: EXPERIMENTAL; Interventions: Behavioral: Trickle Up | Arm Label: Trickle Up Plus; Type: EXPERIMENTAL; Interventions: Behavioral: Trickle Up Plus | Arm Label: Wait-list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trickle Up; Assigned to Arm(s): Trickle Up | Intervention Type: BEHAVIORAL; Name: Trickle Up Plus; Assigned to Arm(s): Trickle Up Plus
C: Arm Label: Sinovuyo Caring Families Programme; Type: EXPERIMENTAL; Interventions: Behavioral: Sinovuyo Caring Families Programme | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sinovuyo Caring Families Programme; Assigned to Arm(s): Sinovuyo Caring Families Programme
D: Arm Label: Mothers and Babies Groups Home-Visitor; Type: EXPERIMENTAL; Interventions: Behavioral: Mothers and Babies Groups | Arm Label: Mothers and Babies Groups Clinician; Type: EXPERIMENTAL; Interventions: Behavioral: Mothers and Babies Groups | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mothers and Babies Groups; Assigned to Arm(s): Mothers and Babies Groups Clinician, Mothers and Babies Groups Home-Visitor

Answer: D